Nanotransposon compositions and methods of use

Nanotransposon compositions with minimized ITR sequences improve transposition efficacy and gene transfer in human cells, addressing inefficiencies in conventional gene therapy methods.

AU2019401282B2Pending Publication Date: 2026-07-16POSEIDA THERAPEUTICS INC
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
POSEIDA THERAPEUTICS INC
Filing Date
2019-12-20
Publication Date
2026-07-16

AI Technical Summary

Technical Problem

Existing gene therapy methods face inefficiencies in transposition and gene transfer to human cells, particularly with conventional transposon vectors.

Method used

Development of nanotransposon compositions with minimized inter-inverted terminal repeat (ITR) sequences and optimized nucleic acid structures, including origins of replication and selectable markers, to enhance transposition efficacy and efficiency in human cells.

Benefits of technology

The nanotransposons achieve high transposition efficiency and gene transfer to a significant percentage of human cells, effectively modifying cell function for therapeutic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000001_0000
    Figure 00000001_0000
  • Figure 00000001_0001
    Figure 00000001_0001
  • Figure 00000116_0000
    Figure 00000116_0000
Patent Text Reader

Abstract

Disclosed are compositions comprising a first nucleic acid sequence comprising: (a) a first inverted terminal repeat (ITR), (b) a second ITR and (c) an intra-ITR sequence, wherein the intra-ITR sequence comprises a transposon sequence, and a second nucleic acid sequence comprising an inter-ITR sequence, wherein the length of the inter-ITR sequence is between 1 and 600 nucleotides, inclusive of the endpoints. Preferably, the compositions are nanotransposons.
Need to check novelty before this filing date? Find Prior Art